Organogenesis (ORGO) announced the initiation of a rolling submission of a Biologics License Application to the FDA for ReNu, a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee arthritis. Organogenesis plans to complete the BLA submission with the final modules submitted in the first half of 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis Nears Key Data Milestone With Phase 3 Knee Osteoarthritis Study
- Morning Movers: Vital Farms dips after cutting FY25 revenue view
- Buy Rating for Organogenesis Holdings: FDA Progress and Favorable Policy Changes Drive Optimism
- Organogenesis plans to file BLA for ReNu before end of December
- Organogenesis price target raised to $9 from $7 at BTIG